US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

21.08

0.0000

Post-market: 21.080.00000.00%19:07 EDT

Volume:383.07K

Turnover:8.12M

Market Cap:1.21B

PE:-8.14

High:21.68

Open:21.25

Low:20.87

Close:21.08

Loading ...

Overview Company News Filings

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Guggenheim

Structure Therapeutics Inc. Concluded Annual Shareholders' Meeting

Citizens JMP Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85TH Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, Accg-2671

THOMSON REUTERS

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin. -- Barrons.com

This biotech's stock rockets on oral obesity drug partnership with Wegovy parent

Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Piper Sandler Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Structure Therapeutics Reports Q1 2025 Net Loss of $46.8 Million, Up from $26 Million in Q1 2024

Structure Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Structure Therapeutics initiated with a Buy at Citi

Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Shares of Obesity Drug Developer Structure Therapeutics up 24.6% Premarket After Eli Lilly's Pill Leads to 7.9% Weight Loss in Late-Stage Trial

THOMSON REUTERS

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GPCR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":21.08,"timestamp":1751054400000,"preClose":21.08,"halted":0,"volume":383066,"hourTrading":{"tag":"盘后","latestPrice":21.08,"preClose":21.08,"latestTime":"19:07 EDT","volume":413,"amount":8736.43,"timestamp":1751065676062},"delay":0,"floatShares":48739903,"shares":57536749,"eps":-2.590061,"marketStatus":"Market Closed","change":0,"latestTime":"06-27 16:00:00 EDT","open":21.25,"high":21.6815,"low":20.865,"amount":8115504.501296001,"amplitude":0.038733,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.590061,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":21.08,"preHourTrading":{"tag":"盘前","latestPrice":21.26,"preClose":21.08,"latestTime":"09:28 EDT","volume":941,"amount":20008.291036000002,"timestamp":1751030880094},"postHourTrading":{"tag":"盘后","latestPrice":21.08,"preClose":21.08,"latestTime":"19:07 EDT","volume":413,"amount":8736.43,"timestamp":1751065676062},"volumeRatio":0.40102278493975657,"impliedVol":0.7045,"impliedVolPercentile":0.092},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":48739903,"roa":"-17.24%","roe":"-22.85%","lyrEps":-2.327592,"volumeRatio":0.40102278493975657,"shares":57536749,"dividePrice":0,"high":21.6815,"amplitude":0.038733,"preClose":21.08,"low":20.865,"week52Low":13.22,"pbRate":"1.47","week52High":47.48,"institutionHeld":0,"latestPrice":21.08,"eps":-2.590061,"divideRate":0,"volume":383066,"delay":0,"ttmEps":-2.590061,"open":21.25,"prevYearClose":27.12,"prevWeekClose":21.73,"prevMonthClose":21.76,"prevQuarterClose":17.31,"fiveDayClose":21.73,"twentyDayClose":22.42,"sixtyDayClose":15.79},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546780964","title":"Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2546780964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546780964?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:55","pubTimestamp":1750938920,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) yesterday and se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/structure-therapeutics-inc-sponsored-adr-gpcr-gets-a-buy-from-guggenheim-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/structure-therapeutics-inc-sponsored-adr-gpcr-gets-a-buy-from-guggenheim-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2546225646","title":"Structure Therapeutics Inc. Concluded Annual Shareholders' Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546225646","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546225646?lang=en_us&edition=fundamental","pubTime":"2025-06-26 04:16","pubTimestamp":1750882580,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. held its Annual General Meeting of Shareholders on June 23, 2025. Eric Dobmeier and Joanne Waldstreicher, M.D. were elected as Class II directors. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Shareholders approved the advisory vote on the preferred frequency of shareholder advisory votes on executive compensation to occur every year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL9FVjHj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2545441321","title":"Citizens JMP Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2545441321","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545441321?lang=en_us&edition=fundamental","pubTime":"2025-06-24 01:39","pubTimestamp":1750700346,"startTime":"0","endTime":"0","summary":"Citizens JMP analyst Jonathan Wolleben reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and set...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citizens-jmp-reaffirms-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citizens-jmp-reaffirms-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","GPCR"],"gpt_icon":0},{"id":"2545105283","title":"Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2545105283","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545105283?lang=en_us&edition=fundamental","pubTime":"2025-06-21 07:30","pubTimestamp":1750462216,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL20pdcm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","IE00B3QW5Z07.USD","GPCR","IE00BKPKM429.USD","BK4007","LU2210150020.SGD","BK4585","NDAQ","BK4599","LU2210149790.SGD","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2545410549","title":"Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85TH Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, Accg-2671","url":"https://stock-news.laohu8.com/highlight/detail?id=2545410549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545410549?lang=en_us&edition=fundamental","pubTime":"2025-06-21 07:30","pubTimestamp":1750462200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nTUABSSS9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2539483229","title":"Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2539483229","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539483229?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:05","pubTimestamp":1748549100,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, May  29, 2025  (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/05/29/3090713/0/en/Structure-Therapeutics-to-Participate-in-Multiple-Upcoming-Healthcare-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HCSG","BK4599","BK4539","BK4007","BK4137","LENZ","GPCR"],"gpt_icon":0},{"id":"2539926025","title":"Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2539926025","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539926025?lang=en_us&edition=fundamental","pubTime":"2025-05-30 02:09","pubTimestamp":1748542140,"startTime":"0","endTime":"0","summary":"After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of weight-loss drugs called amylins is drawing the drug industry's attention and dollars.A couple of multibillion-dollar development deals for amylin drugs were signed this year, and more news will come out at June's scientific session of the American Diabetes Association.GLP-1s have shown impressive benefits beyond weight loss, including benefits for the heart, kidneys and perhaps even the brain. Key questions include whether the amylins help people with diabetes lose more weight than they do on GLP-1s; and whether the amylins have the benefits beyond weight loss that GLP-1s are demonstrating.Like GLP-1s, the amylin class of hormones has attracted many pharma suitors. In March, Roche made a deal worth up to $5.3 billion with Denmark's Zealand Pharma to advance pet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4516","LU2750360641.GBP","RHHBY","SG9999003800.SGD","LU1244550494.USD","LU2461242641.AUD","LU1917777945.USD","LU2237443978.SGD","LU1430594728.SGD","LU0198837287.USD","BK4550","LU1720051017.SGD","LU1868837136.USD","LU0158827948.USD","LU1366192091.USD","LU1934455863.HKD","SG9999001176.USD","LU2106854487.HKD","LU1037948897.HKD","LU0320765646.SGD","LLY","IE00B4R5TH58.HKD","BK4532","LU2471134879.HKD","LU2237443549.SGD","03165","LU0882574055.USD","NVO","SGXZ81514606.USD","LU0820561818.USD","BK4566","LU0170899867.USD","LU0738911758.USD","LU1623119135.USD","LU0058720904.USD","LU0820561909.HKD","LU1496350502.SGD","MTSR","LU0029864427.USD","IE00BSNM7G36.USD","GPCR","SG9999015945.SGD","LU0122379950.USD","LU2089283258.USD","ABBV","LU1064131342.USD","LU2112291526.USD","LU0354030511.USD","LU0006306889.USD"],"gpt_icon":1},{"id":"2535907024","title":"This biotech's stock rockets on oral obesity drug partnership with Wegovy parent","url":"https://stock-news.laohu8.com/highlight/detail?id=2535907024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535907024?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:00","pubTimestamp":1747227600,"startTime":"0","endTime":"0","summary":"Novo Nordisk looks to harness Septerna's broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments. Shares of Septerna Inc. were soaring in early Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes medicines.Oral obesity medication could offer an alternative to injectable medications, such as Novo Nordisk's   Wegovy and Ozempic.In a statement, the companies said they would harness Septerna's  expertise in G protein-coupled receptor  drug discovery. GPCRs are cell membrane receptors that regulate physiological processes in nearly every organ system of the human body.Septerna's stock rocketed 64.2%, making it the biggest premarket gainer on major U.S. exchanges, according to FactSet data.However, during a conference call to discuss Novo Nordisk's first-quarter results last week, Chief Executive Lars Jorgensen said that the oral weight loss drug will be \"way sma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","IE00B4R5TH58.HKD","LU0689472784.USD","LU1232071149.USD","IBB","LU0320765992.SGD","SGXZ51526630.SGD","LU2265009873.SGD","LU2746668461.USD","LU1868837300.USD","LU0385154629.USD","LU2063271972.USD","LU1720051017.SGD","LU0466842654.USD","BK4007","LU0122379950.USD","LU2211815571.USD","GB00BDT5M118.USD","LU2461242641.AUD","LU1804176565.USD","LU2552382215.SGD","LU2491050071.SGD","LU1267930730.SGD","LU0006306889.USD","LU2491050154.USD","IE00BK4W5L77.USD","LU1035775433.USD","BK4588","IE00BK4W5M84.HKD","LU0640476718.USD","LU0820561818.USD","LU1548497426.USD","BK4534","LU0203202063.USD","LU0058720904.USD","NVO","IE0004445239.USD","LU2237443622.USD","SG9999015952.SGD","LU1988902786.USD","LU1623119135.USD","LU0109391861.USD","SEPN","GPCR","LU2361045086.USD","LU1366192091.USD","LU0061475181.USD","LU2237443978.SGD","SG9999014914.USD"],"gpt_icon":1},{"id":"2534222062","title":"Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2534222062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534222062?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:20","pubTimestamp":1747052400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2025 08:20 ET (12:20 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LENZ"],"gpt_icon":0},{"id":"2534434892","title":"Piper Sandler Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2534434892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534434892?lang=en_us&edition=fundamental","pubTime":"2025-05-09 23:18","pubTimestamp":1746803938,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and set a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR"],"gpt_icon":0},{"id":"2534162046","title":"Structure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534162046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534162046?lang=en_us&edition=fundamental","pubTime":"2025-05-09 05:02","pubTimestamp":1746738136,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryStructure Therapeutics Inc GPCR.OQ reported a quarterly adjusted loss of 81 cents per share for the quarter ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG3M8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR"],"gpt_icon":0},{"id":"2534166741","title":"Structure Therapeutics Reports Q1 2025 Net Loss of $46.8 Million, Up from $26 Million in Q1 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2534166741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534166741?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:07","pubTimestamp":1746734846,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL93WH1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","LU2095319765.USD","BK4007","IE00B64PRP62.GBP","LU2210150020.SGD","BK4599","BK4588","BK4112","GPCR","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2533931569","title":"Structure Therapeutics Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533931569","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533931569?lang=en_us&edition=fundamental","pubTime":"2025-05-06 05:26","pubTimestamp":1746480380,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc  expected to post a loss of23cents a share - Earnings Preview Structure Therapeutics Inc GPCR.OQ GPCR.O is expected to show no change in quarterly revenue when it reports  r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD2OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR"],"gpt_icon":0},{"id":"2532147208","title":"Structure Therapeutics initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2532147208","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532147208?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183659,"startTime":"0","endTime":"0","summary":"Citi analyst Samantha Semenkow initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $60 price target Structure is a clinical-s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-initiated-with-a-buy-at-citi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-initiated-with-a-buy-at-citi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4599","GPCR","BK4139"],"gpt_icon":0},{"id":"2530199527","title":"Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2530199527","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530199527?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:31","pubTimestamp":1745613110,"startTime":"0","endTime":"0","summary":"We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc.  stands against other promising small-cap stocks.Robert Teeter of Silvercrest Asset Management recently appeared in an interview to express that he thinks small-cap stocks are currently facing a choppy market, but he also acknowledged that he anticipates a rally later in the year. Based on this sentiment, he advised clients on the importance of diversification within the S&P 500 and pointed to opportunities in international markets. We covered his stance in greater detail in one of our other articles,10 Best Small-Cap Value Stocks to Buy Now. Here’s an excerpt from it:. Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/structure-therapeutics-inc-nasdaq-gpcr-203150034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GPCR","MNQmain","IE00BGHQF748.EUR","ESmain","LU2210149790.SGD","BK4550","BK4007","BK4581","OEX","BK4585","SDS","OEF","TSYW.SI","TQQQ","SSO","IE00B3QW5Z07.USD","USAW.SI","QLD","LU2210150020.SGD","SQQQ","SH","VOO","IVV","PSQ","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4599","NVIW.SI","USJW.SI","BK4588","BK4559","SPXU","BK4504","QID","SPY",".IXIC",".SPX","BK4112","BK4534","NQmain"],"gpt_icon":1},{"id":"2529138887","title":"LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529138887","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529138887?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:37","pubTimestamp":1745239020,"startTime":"0","endTime":"0","summary":"Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the primary goal of significantly reducing A1C levels compared to placebo at 40 weeks, with an average A1C reduction of 1.3% to 1.6% from a baseline of 8%. LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake.The phase III ACHIEVE-1 study, the first of sevenlate-stage studies, is evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes  and inadequate glycemic control with diet and exercise alone. The enrolled patients in the 40-week study were randomized equally to receive either a 3 mg, 12 mg or 36 mg dose of orforglipron or placebo. Lilly is also developing a version of this oral drug for obesity.Year to date, shares of Lilly have gained 8.8% against the industry’s 3.3% decline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lly-stock-oral-glp-1-123700472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443465.HKD","LU0456855351.SGD","LU1551013342.USD","LU2264538146.SGD","LU1280957306.USD","LU2324357040.USD","LU1061106388.HKD","LU2360106947.USD","LU1868836757.USD","IE00BK4W5L77.USD","LU1712237335.SGD","III","LU0943347566.SGD","SG9999017495.SGD","LU1093756325.SGD","LU0471298777.SGD","LU1548497426.USD","LU0114720955.EUR","GLP","LU0094547139.USD","LU0238689110.USD","LU1720051017.SGD","LU2237443622.USD","SG9999018865.SGD","LU2237443382.USD","VKTX","LU0640476718.USD","BK4581","LLY","LU2361044949.HKD","IE00B2B36J28.USD","LU1093756168.USD","LU2471134952.CNY","LU0354030511.USD","LU1366192091.USD","LU1868837300.USD","LU0417517546.SGD","LU2106854487.HKD","GPCR","LU2089984988.USD","NVO","LU0256863811.USD","LU1035775433.USD","LU1720051108.HKD","LU0096364046.USD","IE0004445239.USD","BK4534","BK4532","LU1023059063.AUD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2528060378","title":"JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528060378","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528060378?lang=en_us&edition=fundamental","pubTime":"2025-04-18 22:26","pubTimestamp":1744986368,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Hardik Parikh says Eli Lilly’s  Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics  shares could be up double-digit percent in this scenario on a “highly favorable read-through” and Viking Therapeutics  could move mid-single-digit in either direction. JPMorgan’s focus was primarily on orfoglipron’s tolerability profile with the extended titration, and here the data is highlighted by an 8% discontinuation rate on the highest dose versus low-teens expectations, the analyst tells investors in a research note. The firm sees the data as “helping derisk the category,” giving more confidence that Structure can also bring tolerability of aleniglipron to reasonable levels. For Viking, the read-through is not as direct, and today’s data “clearly helps derisk a strong” first in class oral competitor from Lilly, which could limit the potential of lat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jpmorgan-says-lilly-data-highly-142608655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jpmorgan-says-lilly-data-highly-142608655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLSP4239.USD","SG9999001176.SGD","LU1267930730.SGD","LU0198837287.USD","SGXZ57979304.SGD","LU2237443465.HKD","LU1066051498.USD","LU0238689110.USD","SGXZ51526630.SGD","IE00BJT1NW94.SGD","LU0256863902.USD","SG9999018857.SGD","LU2324357040.USD","LU0640476718.USD","LENZ","LU2237443895.HKD","LU2602419157.SGD","LU0234572021.USD","SG9999001176.USD","LU1291159041.SGD","IE00B19Z3581.USD","SG9999018865.SGD","LU0256863811.USD","LU0689472784.USD","IE0009355771.USD","BK4585","LU2237438978.USD","LU1883839398.USD","LU2471134879.HKD","GPCR","LU2360106947.USD","SG9999002224.SGD","VKTX","LU1720051108.HKD","LU2357305700.SGD","LU0321505439.SGD","BK4550","LU2237443622.USD","LU2491050071.SGD","SG9999015945.SGD","SG9999014880.SGD","LU2023250504.SGD","LU0820561818.USD","BK4516","LU1232071149.USD","LU1066053197.SGD","LLY","LU2552382215.SGD","SG9999015952.SGD"],"gpt_icon":1},{"id":"2528671237","title":"BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528671237","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528671237?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:53","pubTimestamp":1744894413,"startTime":"0","endTime":"0","summary":"BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trialUpdates** Shares of drugmaker Eli Lilly LLY.N rise 12.7% to $828.67 premarket** Company says its small molecule oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial** Shares of Structure Therapeutics GPCR.O, which is also developing a small molecule oral weight loss drug, gain 17.7% before the bell** U.S.-listed shares of Lilly's obesity drug rival Novo Nordisk NOVOb.CO down 6%** Other weight-loss drug developers such as Viking Therapeutics VKTX.O down 5.1% and Amgen AMGN.O down 2.8%** Up to last close, LLY shares down 4.8%, VKTX down 41.2% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nL4N3QV176:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU0882574139.USD","LU0122379950.USD","GPCR","LU0096364046.USD","LU0289739699.SGD","LU0109391861.USD","LU2242646821.SGD","LU2237438978.USD","LU1988902786.USD","LU1548497426.USD","BK4533","LU0109394709.USD","LU0106261372.USD","LU0203202063.USD","LU2237443978.SGD","LU1551013425.SGD","LU0417517546.SGD","LU0820561909.HKD","LU2491050154.USD","LU1057294990.SGD","LU0820561818.USD","LU2357305700.SGD","LU0943347566.SGD","IE00B1BXHZ80.USD","LU2361044865.SGD","SG9999014898.SGD","LU1720051108.HKD","VKTX","LU2237443622.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","SGXZ99366536.SGD","LU0256863811.USD","LU1023059063.AUD","BK4599","LLY","LU1366192091.USD","LU0058720904.USD","LU0889565916.HKD","IE0009355771.USD","LU1868836914.USD","LU2750360997.AUD","SGXZ31699556.SGD","LU1093756325.SGD","SG9999001440.SGD","LU2360106947.USD","LU1093756168.USD","SGXZ51526630.SGD","SG9999014906.USD"],"gpt_icon":1},{"id":"2528802715","title":"Shares of Obesity Drug Developer Structure Therapeutics up 24.6% Premarket After Eli Lilly's Pill Leads to 7.9% Weight Loss in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528802715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528802715?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:42","pubTimestamp":1744890170,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2P0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2527444107","title":"NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2527444107","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527444107?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:00","pubTimestamp":1744725600,"startTime":"0","endTime":"0","summary":"Obesity stocks like Novo Nordisk NVO, Eli Lilly LLY, Structure Therapeutics GPCR and Viking Therapeutics VKTX gained 2.1%, 3%, 10.6% and 19.2%, respectively, on Monday after pharma bigwig Pfizer PFE announced that it is discontinuing the development of its GLP-1R weight loss pill, danuglipron.After reviewing all clinical data and considering regulatory feedback, Pfizer concluded that halting the program was the best course of action. This decision reverted Pfizer’s developmental program for an obesity candidate back to the early clinical stages and has significantly delayed its hopes for marketing an obesity drug that would compete with Lilly’s Zepbound and Novo Nordisk’s Wegovy for market share.How PFE’s Obesity Study Setback Benefits VKTX, GPCR, LLY & NVO. Shares of Lilly, Novo Nordisk, Viking Therapeutics and Structure Therapeutics rose as Pfizer's decision to discontinue its obesity pill program removes a ke","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-lly-gpcr-vktx-stocks-140000975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999011175.SGD","SGXZ81514606.USD","LU0289739699.SGD","PFE","LLY","LU0672654240.SGD","LU0820561909.HKD","BK4588","LU1127390331.HKD","LU1291159041.SGD","LU1712237335.SGD","LU1868837300.USD","LU2237443465.HKD","LU2360106947.USD","LU0106261372.USD","LU2471134952.CNY","BK4568","LU1917777945.USD","LU1868836757.USD","IE0002141913.USD","LU1232071149.USD","VKTX","LU0868494617.USD","BK4599","LU1983299246.USD","LU2552382058.USD","IE00BZ1G4Q59.USD","NVO","LU1069344957.HKD","LU0985481810.HKD","GPCR","LU0096364046.USD","SG9999013999.USD","SG9999014914.USD","LU2361044865.SGD","IE00BLSP4452.SGD","BK4581","LU1551013425.SGD","LU0203202063.USD","LU0882574055.USD","LU0354030438.USD","LU1093756325.SGD","LU1894683348.USD","IE000M9KFDE8.USD","SGXZ99366536.SGD","LU1883839398.USD","LU0456855351.SGD","LU0058720904.USD","IE00BJT1NW94.SGD","BK4532"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"GPCR","fiscalQuarterEnding":"2025/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-02-27","symbol":"GPCR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-11-13","symbol":"GPCR","fiscalQuarterEnding":"2024/09","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":14,"updateTime":1746244800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2025-06-26","current":-8.747555,"percent":0.963605,"low":-50.180001,"twenty":-24.920519,"median":-20.436031,"eighty":-14.681108,"high":-6.622278,"avg":-20.756908,"sd":8.182495,"marketCap":1253725760},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-05-02","current":-12.790591,"twenty":-25.171712,"median":-20.933479,"eighty":-16.305436,"marketCap":1567180008},{"date":"2025-05-09","current":-12.551909,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"marketCap":1537935156},{"date":"2025-05-16","current":-9.774326,"twenty":-25.068859,"median":-20.829252,"eighty":-16.056814,"marketCap":1400885752},{"date":"2025-05-23","current":-9.895696,"twenty":-25.0453,"median":-20.693431,"eighty":-15.839386,"marketCap":1418280862},{"date":"2025-05-30","current":-9.000467,"twenty":-25.01052,"median":-20.672234,"eighty":-15.745511,"marketCap":1289973912},{"date":"2025-06-06","current":-8.619091,"twenty":-25.001825,"median":-20.550917,"eighty":-15.544032,"marketCap":1235314001},{"date":"2025-06-13","current":-8.920177,"twenty":-24.996225,"median":-20.487391,"eighty":-15.387426,"marketCap":1278466562},{"date":"2025-06-20","current":-8.679308,"twenty":-24.952868,"median":-20.449033,"eighty":-14.973238,"marketCap":1243944513},{"date":"2025-06-26","current":-8.747555,"twenty":-24.920519,"median":-20.436031,"eighty":-14.681108,"marketCap":1253725760}],"updateTime":1751071627278}}}